Orbital Therapeutics

About Orbital Therapeutics

Orbital Therapeutics is focused on expanding RNA medicines to reach more tissues, diseases, and patients. They aim to make immune reprogramming a clinical reality through a fully integrated RNA platform, precision design of therapies, and a mission-driven team dedicated to restoring health by resetting the immune system.

Products & Services

RNA Immunotherapies:A new generation of therapies designed to reset the immune system and restore health by delivering precise molecular instructions to immune cells in vivo.

Integrated RNA Platform:A platform spanning circular and linear RNA, AI-guided design, and targeted delivery to engineer durable therapies for immune reprogramming.

Specialties

RNA Medicines Immune Reprogramming RNA Immunotherapies AI-Guided Design Targeted Delivery

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 270000000 MR: - FA: $270 million FAN: 270000000	D: 2023-04-26 FD: 2023-04-26	15 investors

Series A Latest

2023-04-26

$270.0M

15 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Ron Philip

President & Chief Executive Officer

G

Gilles Besin

Chief Scientific Officer

A

Anna Dixon

Senior Vice President, Human Resources

J

Jeff Munsie

Chief Legal Officer

J

Jonathan Piazza

Chief Financial Officer

A

Adam Raff

Senior Vice President, Clinical Development

View 17 more team members with Pro

Unlock Full Team Directory

Recent News